PUBLISHER: KBV Research | PRODUCT CODE: 1374267
PUBLISHER: KBV Research | PRODUCT CODE: 1374267
The Global Pigmentation Disorder Treatment Market size is expected to reach $1.2 billion by 2030, rising at a market growth of 4.8% CAGR during the forecast period.
There has been a significant increase in awareness regarding pigmentation disorders, skin health, and skincare in the APAC region. Consequently, the APAC region registered $212.6 million revenue in the market in 2022. People are becoming more conscious of their skin's appearance and health, increasing their willingness to seek treatment for pigmentation issues. Rapid urbanization in many APAC countries has brought changes in lifestyle and exposure to environmental factors that can exacerbate pigmentation disorders. Urban populations often have more access to healthcare facilities, including dermatologists. APAC countries often experience high levels of sunlight, which can contribute to pigmentation disorders such as melasma and solar lentigines. This has prompted people to seek treatments like sunscreens and laser therapy. Some of the factors impacting the market are growing awareness of skin health, advancements in treatment modalities, and limited efficacy of currently available treatments.
Greater awareness of the importance of skin health and aesthetics has prompted more individuals to seek treatment for pigmentation issues. People are becoming more proactive about addressing skin concerns. As individuals become more informed about skin health, they are more likely to recognize the early signs of pigmentation disorders. This can lead to earlier diagnosis and intervention, potentially improving treatment outcomes. Advances in dermatological treatments have improved the effectiveness and safety of pigmentation disorder treatments. Innovative technologies offer better outcomes, such as laser therapy, chemical peels, microneedling, and topical formulations. Advancements in treatment modalities often result in more effective treatments in addressing pigmentation disorders. For example, newer laser technologies and techniques can target pigmentation with greater precision, leading to improved outcomes. Thus, the advancements in treatment modalities benefit patients by providing more effective and comfortable treatment options and driving growth in the market.
However, the limited efficacy of currently available pigmentation disorder treatment options is a significant concern in the field of dermatology. One of the primary factors contributing to this limitation is the complex and multifaceted nature of these conditions. Pigmentation disorders often involve intricate mechanisms within the skin, making them resistant to straightforward treatment approaches. As a result, there is no one-size-fits-all solution, and the quest for effective treatments continues to challenge dermatologists and researchers. Moreover, the pandemic disrupted global supply chains, including skin care products and dermatological equipment production and distribution. This led to shortages of certain treatment products and delayed the availability of new treatments. Economic uncertainties caused by the pandemic led some individuals to reduce discretionary spending, including spending on cosmetic and dermatological treatments. This economic impact affected the affordability and demand for pigmentation disorder treatments.
By type, the market is categorized into vitiligo, melasma, and others. In 2022, the vitiligo segment held the highest revenue share in the market. Vitiligo is a specific pigmentation disorder characterized by the loss of melanocytes (pigment-producing cells) in certain areas of the skin, resulting in the development of white patches. The treatment of vitiligo is a significant component of the broader market. Topical corticosteroids, calcineurin inhibitors, and topical calcipotriene commonly treat vitiligo. These products are directly applied to the afflicted areas of the skin to reduce inflammation and encourage repigmentation. They are an essential part of the market.
Based on treatment, the market is segmented into corticosteroids, calcineurin inhibitor, and others. The calcineurin inhibitor segment garnered a significant revenue share in the market in 2022. Calcineurin inhibitors have effectively treated pigmentation disorders like vitiligo, particularly in areas where corticosteroids may be less suitable due to skin thinning or other concerns. These medications work by modulating the immune response in the skin, which can be particularly useful for pigmentation disorders with autoimmune or inflammatory components. Calcineurin inhibitors are generally considered safe for long-term use on delicate or sensitive skin areas, such as the face and genital area, where corticosteroids might carry a higher risk of side effects.
Distribution Channel Outlook
On the basis of distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. The drug store and retail pharmacies segment recorded the maximum revenue share in the market in 2022. Drug stores and retail pharmacies typically offer a range of OTC skincare products, including those designed for pigmentation disorders. This increased accessibility allows individuals to explore and try certain treatments without a prescription, potentially boosting sales of these products. Many prescription pigmentation disorder treatments, such as topical corticosteroids, calcineurin inhibitors, and specialized creams, can be dispensed by retail pharmacies.
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. Dermatological clinics and medical spas are key providers of pigmentation disorder treatments in North America. These facilities offered various services, including consultations, in-office procedures, and skincare products. The well-established healthcare infrastructure in North America, including many dermatology clinics and well-trained dermatologists, supported the market's growth. Advancements in laser technology and innovative treatment devices enhanced the efficacy and safety of pigmentation disorder treatments in North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy's Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
Market Segments covered in the Report:
By Distribution Channel
Unique Offerings from KBV Research